Abstract
Immune checkpoint inhibitors among non-small cell lung cancer (NSCLC) have changed the landscape of cancer treatment demonstrating superior efficacies. Nevertheless, immune related toxicity carries clear potential for morbidity and mortality. Among other side effects are the cardiovascular toxicity including myocarditis as the most common cardiovascular side effect. The burden of cardiovascular side effects is relatively low, but its real prevalence is unproven. The clinical relevance of troponin elevation as an early sign of myocarditis is yet to be determined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
